|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 BioRestorative Therapies, Inc. 10-Q 6/30/22 59:4.5M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 815K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
10: R1 Cover HTML 72K
11: R2 Condensed Consolidated Balance Sheets HTML 104K
12: R3 Condensed Consolidated Balance Sheets HTML 36K
(Parenthetical)
13: R4 Condensed Consolidated Statements of Operations HTML 70K
(Unaudited)
14: R5 Condensed Consolidated Statements of Changes in HTML 77K
Stockholders' Equity (Deficit) (Unaudited)
15: R6 Condensed Consolidated Statements of Cash Flows HTML 85K
(Unaudited)
16: R7 Nature of the Organization, Liquidity, and HTML 34K
Business
17: R8 Summary of Significant Accounting Policies HTML 87K
18: R9 Intangible Assets HTML 49K
19: R10 Accrued Expenses and Other Current Liabilities HTML 26K
20: R11 Notes Payable HTML 31K
21: R12 Stockholders? Equity (Deficit) HTML 195K
22: R13 Commitments and Contingencies HTML 26K
23: R14 Leases HTML 37K
24: R15 Subsequent Events HTML 23K
25: R16 Summary of Significant Accounting Policies HTML 136K
(Policies)
26: R17 Summary of Significant Accounting Policies HTML 40K
(Tables)
27: R18 Intangible Assets (Tables) HTML 49K
28: R19 Accrued Expenses and Other Current Liabilities HTML 24K
(Tables)
29: R20 Notes Payable (Tables) HTML 23K
30: R21 Stockholders? Equity (Deficit) (Tables) HTML 179K
31: R22 Leases (Tables) HTML 34K
32: R23 Nature of the Organization, Liquidity, and HTML 59K
Business (Details Narrative)
33: R24 Schedule of Weighted Average Dilutive Common HTML 34K
Shares (Details)
34: R25 Schedule of Weighted Average Dilutive Common HTML 20K
Shares (Details) (Parenthetical)
35: R26 Summary of Significant Accounting Policies HTML 41K
(Details Narrative)
36: R27 Schedule of Finite Lived Intangible Assets HTML 41K
(Details)
37: R28 Schedule of Finite Lived Intangible Assets HTML 32K
Amortization Expenses (Details)
38: R29 Schedule of Accrued Expenses and Other Current HTML 26K
Liabilities (Details)
39: R30 Schedule of Notes Payable Activity (Details) HTML 26K
40: R31 Notes Payable (Details Narrative) HTML 34K
41: R32 Schedule of Warrant Activity (Details) HTML 55K
42: R33 Schedule of Stock Warrants (Details) HTML 65K
43: R34 Schedule of Stock Option Granted Assumptions HTML 29K
(Details)
44: R35 Schedule of Stock Option Activity (Details) HTML 48K
45: R36 Schedule of Stock Option by Exercise Price HTML 60K
(Details)
46: R37 Schedule of Stock Option by Exercise Price HTML 23K
(Details) (Parenthetical)
47: R38 Schedule of Unvested Restricted Stock Units HTML 29K
(Details)
48: R39 Schedule of Stock Compensation Expense (Details) HTML 33K
49: R40 Stockholders? Equity (Deficit) (Details Narrative) HTML 69K
50: R41 Commitments and Contingencies (Details Narrative) HTML 32K
51: R42 Schedule of Net Lease Cost and Other Supplemental HTML 33K
Lease Information (Details)
52: R43 Schedule of Future Minimum Payments Under HTML 30K
Non-Cancelable Leases for Operating Leases
(Details)
53: R44 Leases (Details Narrative) HTML 31K
54: R45 Subsequent Events (Details Narrative) HTML 27K
57: XML IDEA XML File -- Filing Summary XML 103K
55: XML XBRL Instance -- form10-q_htm XML 1.10M
56: EXCEL IDEA Workbook of Financial Reports XLSX 101K
6: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 120K
Linkbase Document -- brtx-20220630_cal
7: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 388K
Document -- brtx-20220630_def
8: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 785K
Document -- brtx-20220630_lab
9: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 611K
Linkbase Document -- brtx-20220630_pre
5: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 108K
brtx-20220630
58: JSON XBRL Instance as JSON Data -- MetaLinks 284± 412K
59: ZIP XBRL Zipped Folder -- 0001493152-22-022617-xbrl Zip 184K
Exhibit 31.1
BIORESTORATIVE THERAPIES, INC.
PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Lance Alstodt, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of BioRestorative Therapies, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 16a–15(f) and 15d–15(f)) for the registrant and have: |
| (a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| (b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| (b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| By: | /s/ Lance Alstodt | |
| Lance Alstodt | ||
| Principal Executive Officer | ||
| Date: | August 15, 2022 |
C:
| C: |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/15/22 | |||
| For Period end: | 6/30/22 | 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/13/23 BioRestorative Therapies, Inc. 424B5 7/12/23 1:363K M2 Compliance LLC/FA 4/14/23 BioRestorative Therapies, Inc. 424B2 1:370K M2 Compliance LLC/FA 2/07/23 BioRestorative Therapies, Inc. S-3 4:283K Certilman Balin … LLP/FA 9/30/22 BioRestorative Therapies, Inc. POS AM 2:759K Certilman Balin … LLP/FA 8/16/22 BioRestorative Therapies, Inc. POS AM 2:764K Certilman Balin … LLP/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/22 BioRestorative Therapies, Inc. 10-K 12/31/21 92:16M M2 Compliance LLC/FA 11/15/21 BioRestorative Therapies, Inc. 8-K:3,7,9 11/09/21 12:12M Certilman Balin … LLP/FA 12/23/14 BioRestorative Therapies, Inc. 8-K:3,5,9 12/19/14 6:329K Certilman Balin … LLP/FA |